TY - JOUR
T1 - Alternated versus syncopated CHOP-PVB
T2 - Two studies for the treatment of non-hodgkin's lymphoma by the southwest oncology group
AU - Dabich, Lyubica
AU - Dahlberg, Steve
AU - Hartsock, Robert J.
AU - Lobuglio, Albert F.
AU - Liepman, Marcia K.
AU - Grozea, Petre N.
AU - Eyre, Harmon J.
AU - Weick, James K.
AU - Bonnet, John D.
AU - Coltman, Charles A.
AU - Fisher, Richard I.
N1 - Funding Information:
This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA-27057, CA-37429, CA-35117, CA-35995, CA-13238, CA-04919, CA-28862, CA-46282, CA-12644, CA-22433, CA-03096, CA-13612, CA-20319, CA-04920, CA-37981, CA-04915, CA-35996, CA-03389, CA-35158, CA-16385, CA-36020, CA-46113, CA-35128. CA-35431, CA-22411, CA-32734, CA-14028, CA-12213, CA-35262, CA-35274, CA-35261, CA-32102.
PY - 1991
Y1 - 1991
N2 - Based on a preliminary trial that suggested that CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and PVB (cisplatinum, vinblastine, bleomycin), are at least partially non-cross-resistant, the Southwest Oncology Group treated patients with unfavorable histology, non-Hodgkin's lymphoma with CHOP and PVB. In the first study, 76 eligible patients were given three courses of CHOP, with complete or partial responders receiving three courses of PVB followed by three further courses of CHOP. Nonresponders after the initial three cycles of CHOP, received six courses of PVB. In the second study, 154 eligible patients were treated with alternating cycles of the two drug regimens. The overall objective antitumor response (CR+PR) was 77% for the first study and 58% for the second. The complete remission rates were 48% and 38% respectively. The overall survival for both studies is similar. These results are interpreted in terms of the Goldie-Coldman hypothesis.
AB - Based on a preliminary trial that suggested that CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and PVB (cisplatinum, vinblastine, bleomycin), are at least partially non-cross-resistant, the Southwest Oncology Group treated patients with unfavorable histology, non-Hodgkin's lymphoma with CHOP and PVB. In the first study, 76 eligible patients were given three courses of CHOP, with complete or partial responders receiving three courses of PVB followed by three further courses of CHOP. Nonresponders after the initial three cycles of CHOP, received six courses of PVB. In the second study, 154 eligible patients were treated with alternating cycles of the two drug regimens. The overall objective antitumor response (CR+PR) was 77% for the first study and 58% for the second. The complete remission rates were 48% and 38% respectively. The overall survival for both studies is similar. These results are interpreted in terms of the Goldie-Coldman hypothesis.
UR - http://www.scopus.com/inward/record.url?scp=0026333696&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026333696&partnerID=8YFLogxK
U2 - 10.3109/07357909109039872
DO - 10.3109/07357909109039872
M3 - Article
C2 - 1721000
AN - SCOPUS:0026333696
VL - 9
SP - 613
EP - 620
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 6
ER -